Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 1;106(1):e109-e110.
doi: 10.1097/TP.0000000000003975.

Six-month Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients

Jennifer L Alejo  1 , Jonathan Mitchell  1 , Teresa Po-Yu Chiang  1 , Aura Toma Abedon  1 , Carolyn N Sidoti  1 , Brian J Boyarsky  1 , Robin K Avery  2 , Aaron A R Tobian  3 , Macey L Levan  1   4 , Daniel S Warren  1 , Allan B Massie  1   5 , Jacqueline M Garonzik-Wang  6 , Dorry Lidor Segev  1   5 , William A Werbel  2
Affiliations

Six-month Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients

Jennifer L Alejo et al. Transplantation. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

D.L.S. received consulting and speaking honoraria from Sanofi, Novartis, CLS Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, and Thermo Fisher Scientific. M.L.L. is the Social Media Editor for Transplantation. R.K.A. has grant/research support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. The other authors declare no conflicts of interest.

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. Boyarsky BJ, Chiang TP, Teles AT, et al. . Antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients. Transplantation. 2021:105:e137–e138. - PMC - PubMed
    1. FDA Office of Media Affairs. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19.... Published 2021. Accessed August 12, 2021.
    1. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Diseases. COVID-19 vaccines for moderately to severely immunocompromised people. Available at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immun.... Published 2021. Accessed September 10, 2021.
    1. Widge AT, Rouphael NG, Jackson LA, et al. ; mRNA-1273 Study Group. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384:80–82. - PMC - PubMed
    1. Doria-Rose N, Suthar MS, Makowski M, et al. ; mRNA-1273 Study Group. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N Engl J Med. 2021;384:2259–2261. - PMC - PubMed

Publication types